SLS Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
11.3M
+6.4%
10.6M
+14.9%
9.3M
+12.1%
8.3M
+16.5%
7.1M
R&D
7.0M
+12.1%
6.3M
+22.3%
5.1M
+8.4%
4.7M
+12.2%
4.2M
SG&A
4.3M
-1.8%
4.4M
+5.7%
4.1M
+17.0%
3.5M
+23.0%
2.9M
Operating Income
-11309000
-6.4%
-10629000
-14.9%
-9252000
-12.1%
-8255000
-16.5%
-7083000
EBITDA
-11309000
-6.4%
-10629000
-14.9%
-9252000
-12.1%
-8255000
-16.5%
-7083000
Net Income
-10091000
-5.1%
-9605000
-14.3%
-8407000
-9.8%
-7658000
-12.8%
-6791000
EPS (Basic)
$-0.05
+0.0%
$-0.05
+0.0%
$-0.05
+0.0%
$-0.05
+16.7%
$-0.06
EPS (Diluted)
$-0.05
+0.0%
$-0.05
+0.0%
$-0.05
+0.0%
$-0.05
+16.7%
$-0.06
Shares (Diluted)
202.4M
+7.0%
189.2M
+9.7%
172.5M
+21.9%
141.5M
+30.5%
108.4M
SELLAS Life Sciences (SLS) — Financials